Results 41 to 50 of about 156,767 (359)

Tissue plasminogen activator-based clot busting: Controlled delivery approaches. [PDF]

, 2014
Cardiovascular diseases are the leading cause of death worldwide. Thrombosis, the formation of blood clot (thrombus) in the circulatory system obstructing the blood flow, is one of the main causes behind various ischemic arterial syndromes such as ...
El-Sherbiny, IM, Elkholi, IE, Yacoub, MH
core   +1 more source

Plasminogen influence on the PAI-1 release by human platelets [PDF]

The Ukrainian Biochemical Journal
РАІ-1 (plasminogen activator inhibitor type 1), as a major physiological inhibitor of tissue plasminogen activator and urokinase, plays a key role in the regulation of fibrinolysis in vivo.
O. I. Yusova , T. V. Grinenko, T. F. Drobot’ko , A. O. Tykhomyrov   +3 more
doaj   +1 more source

Enablers of the implementation of tissue plasminogen activator in acute stroke care: a cross-sectional survey. [PDF]

PLoS ONE, 2014
To assess emergency physicians' perceptions of individual and system enablers to the use of tissue Plasminogen Activator in acute stroke.Australian fellows and trainees of Australasian College for Emergency Medicine completed a 57-item online survey ...
Alice Grady, Jamie Bryant, Mariko Carey, Chris Paul, Rob Sanson-Fisher   +4 more
doaj   +1 more source

JNK suppression is essential for 17β-Estradiol inhibits prostaglandin E2-Induced uPA and MMP-9 expressions and cell migration in human LoVo colon cancer cells

Journal of Biomedical Science, 2011
Background Epidemiological studies demonstrate that the incidence and mortality rates of colorectal cancer in women are lower than in men. However, it is unknown if 17β-estradiol treatment is sufficient to inhibit prostaglandin E2 (PGE2)-induced cellular
Chen Wei-Kung, Chen Li-Mien, Kuo Wei-Wen, Lin Yueh-Min, Hu Wei-Syun, Hsu Hsi-Hsien, Hwang Jin-Ming, Tsai Fuu-Jen, Liu Chung-Jung, Huang Chih-Yang   +9 more
doaj   +1 more source

Role of low-dose tissue plasminogen activator in patients with refractory hypoxia due to presumed microthrombi in pulmonary vasculature in coronavirus disease 2019: A case series and review of the literature

Lung India, 2022
Severe hypoxia due to coronavirus disease 2019 (COVID-19) is challenging in the intensive care unit (ICU). It is often unresponsive to mechanical ventilation at high positive end-expiratory pressure and the fraction of inspired oxygen combination.
Zia Hashim, Tanmoy Ghatak, Alok Nath, Ratender Kumar Singh   +3 more
doaj   +1 more source

Myosin as cofactor and substrate in fibrinolysis [PDF]

, 1997
Myosin accelerates plasminogen activation by tissue-type plasminogen activator (tPA), and is degraded extensively by plasmin. Myosin binds both tPA and plasminogen, and enhances activation of des1-77-plasminogen by tPA but not by urokinase-type ...
Allen, Deutsch, Hajjar, Hoylaerts, Katalin Ajtai, Kolev, Kolev, Kolev, Krasimir Kolev, Lind, Machovich, Machovich, Machovich, Machovich, Margossian, Mornet, Nyitray, Radcliffe, Raymund Machovich, Stack, Suenson, Tonomura, Weeds, Whyte G. Owen   +23 more
core   +1 more source

Functional, pathogenic, and pharmacological roles of protein folding intermediates

Proteins: Structure, Function, and Bioinformatics, EarlyView., 2023
Abstract Protein expression and function in eukaryotic cells are tightly harmonized processes modulated by the combination of different layers of regulation, including transcription, processing, stability, and translation of messenger RNA, as well as assembly, maturation, sorting, recycling, and degradation of polypeptides.
Emiliano Biasini, Pietro Faccioli
wiley   +1 more source

Successful thrombolytic therapy with recombinant tissue plasminogen activator in ischemic stroke after idarucizumab administration for reversal of dabigatran: a case report

Journal of Medical Case Reports, 2019
Background Idarucizumab is a specific antidote for the anticoagulant dabigatran. Although its efficacy has been recently reported, the drug is still in postmarketing surveillance and requires case data in different emergency settings. A newer intravenous
Toshiyuki Ohtani, Ryosuke Sintoku, Tasuku Yajima, Naoyuki Kaneko   +3 more
doaj   +1 more source

Transcriptional regulation of the urokinase receptor (u-PAR) - A central molecule of invasion and metastasis [PDF]

, 2003
The phenomenon of tumor-associated proteolysis has been acknowledged as a decisive step in the progression of cancer. This short review focuses on the urokinase receptor (u-PAR), a central molecule involved in tumor-associated invasion and metastasis ...
Behrendt N., Bianchi E., Borglum A.D., Boyd D., Chapman H.A., Conese M., Cubellis M.V., Duffy M.J., Duffy M.J., Ellis V., Hollas W., Kariko K., Kook Y.H., Lakka S.S., Langer D.J., Leupold J.H., Lund L.R., Means A.L., Min H.Y., Mohanam S., Nekarda H., Pedersen H., Pyke C., Pyke C., Quattrone A., Resnati M., Roldan A., Schewe D., Shetty S., Soravia E., Suh T., Xue W.   +31 more
core   +1 more source

Systemic effects of tissue plasminogen activator-associated fibrinolysis and its relation to thrombin generation in orthotopic liver transplantation [PDF]

, 1989
Orthotopic liver transplantation is frequently associated with hyperfibrinolysis, the origin and clinical relevance of which is largely unknown. In 20 orthotopic liver transplantations, we studied the occurrence and systemic effects of hyperfibrinolysis.
Bontempo, FA, Kang, YG, Knot, EAR, Lewis, JH, Porte, RJ, Starzl, TE   +5 more
core   +1 more source